SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Momenta Pharmaceuticals Inc.
An SI Board Since March 2004
Posts SubjectMarks Bans Symbol
3027 64 0 MNTA
Emcee:  michael_f_murphy Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2027<i>>Would you care to comment further on that circumstantial evidence? DewDiligence_on_SI-8/12/2009
2026I don't consider that to be circumstantial evidence. Same thing would have hrkrw-8/12/2009
2025Would you care to comment further on that circumstantial evidence? Does this goBiotech Jim-8/12/2009
2024There was already some circumstantial evidence that Amphastar’s ANDA would not bDewDiligence_on_SI-8/12/2009
2023finance.yahoo.comArthur Radley-8/12/2009
2022I agree that it may be a desperation move by Amphastar, but at the end of the daBiotech Jim-8/12/2009
2021Seems like a desperation act by Amphastar more than anything. I don't see horkrw38/12/2009
2020Amphastar thinks that MNTA has been unduly favoured!!! Really? I've not sIan@SI38/11/2009
2019online.wsj.com Another bump in the road.....?????Arthur Radley-8/11/2009
2018MNTA <i>ReadMeFirst</i> updated: <i>2Q09 financial results anDewDiligence_on_SI-8/9/2009
2017Thanks for sharing the report........I own a small position in the stock so anytArthur Radley-8/7/2009
2016Seeking Alpah: Momenta Pharmaceuticals, Inc. Q2 2009 Earnings Call Transcript Amopgcw18/7/2009
2015MNTA ‘ReadMeFirst’ updated: <i>FDA completes inspection of generic-LovenoDewDiligence_on_SI-7/28/2009
2014if people switch from copaxone to MNTA's copy, avonex may/will also lose marmopgcw-7/28/2009
2013<i>>You need to add avonex to that chart. that is the real competition DewDiligence_on_SI-7/28/2009
2012You need to add avonex to that chart. that is the real competition for Copaxonemopgcw-7/28/2009
2011Copaxone vs Tysabri in the US Market <pre><b> Tysabri CopaxDewDiligence_on_SI-7/28/2009
2010NYT: Costly Drugs Known as Biologics Prompt Exclusivity Debate By ANDREW POLLAmopgcw-7/22/2009
2009<i>>Other companies have similar compounds further in development to prDewDiligence_on_SI-7/9/2009
2008<b> * JULY 9, 2009, 11:15 A.M. ET Merck Acquires Rights to AnticoagulaIan@SI-7/9/2009
2007CS: Biotechnology MARKET WEIGHT M. Aberman Biotech Washington Watch - Senate Folmopgcw-7/7/2009
2006MNTA <i> ReadMeFirst </i> updated: <i>M118 data from phase-2 DewDiligence_on_SI-7/2/2009
2005It cracks me when sell-side analysts raise their price target by a tiny percentaDewDiligence_on_SI-6/30/2009
2004Even this research note didn't help much... 8:27AM Momenta Pharma tgt raiseIan@SI-6/30/2009
2003so much for $13... still long though...I still like the risk/reward here. take mopgcw-6/30/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News